Key result
Pembrolizumab yields nearly complete disease regression in a lung cancer case with malignant pericardial effusion.
Why the study?
Cardiac involvement in lung cancer, most commonly presenting as malignant pericardial effusion, is associated with poor prognosis and can present before primary malignancy verification.
Case Report (n=1)
Pembrolizumab treatment resulted in near-complete disease regression in a patient with lung adenocarcinoma who initially presented with a malignant pericardial effusion.
Answers are grounded in this paper and cite their sources.
May support PD-1 inhibition in lung adenocarcinoma with pericardial effusion; leaves open generalizability and requires prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kultan et al. (2021) conducted a case report in Lung adenocarcinoma with malignant pericardial effusion (n=1). Pembrolizumab was evaluated on Clinical response / disease regression. Treatment with pembrolizumab in a 71-year-old woman with lung adenocarcinoma and malignant pericardial effusion led to nearly complete disease regression.
Synapse has enriched 10 related papers. Consider them for comparative context: